In this issue:
- Second-line lenvatinib for advanced HCC
- Metabolic syndrome and cholangiocarcinoma risk
- The risk of decompensation in MASLD-related HCC
- FIB-4 score changes and HCC risk in patients with MASLD
- Effect of hypertension on long-term adverse outcomes in MASLD
- First-in-human study of ADP-A2AFP in patients with advanced HCC
- Extended follow-up of atezolizumab + bevacizumab in advanced HCC
- Predicting survival outcomes in HCC patients treated with lenvatinib
- On-demand TACE alone or with atezolizumab + bevacizumab in unresectable HCC
Please login below to download this issue (PDF)